GH Secretagogues: Selecting the Right Agent Within the Class

Understanding the Two Receptor Pathways

GH secretagogues work through one of two distinct receptor systems, and that distinction drives almost every clinical trade-off in the class. GHRH-receptor agonists (sermorelin, CJC-1295, tesamorelin) mimic endogenous growth hormone releasing hormone to trigger pituitary somatotroph release. GHS-R1a agonists (ipamorelin, GHRP-6, GHRP-2, hexarelin, MK-677) activate the ghrelin receptor to produce a separate, additive GH pulse.

GHRH-Receptor Agonists

Sermorelin is the 29-amino-acid N-terminal fragment of endogenous GHRH. Its short half-life (roughly 10 to 20 minutes) means GH release stays tightly coupled to the hypothalamic clock, preserving normal diurnal pulsatility. A 6-month open-label study in 89 adults with GH deficiency found sermorelin (0.03 mg/kg/night subcutaneously) raised mean IGF-1 from 136 to 215 ng/mL [1].

CJC-1295 without DAC (also called Mod GRF 1-29) is a stabilized 29-amino-acid GHRH analog with a half-life of roughly 30 minutes, still preserving pulse architecture when dosed at the same frequency as sermorelin. CJC-1295 with DAC binds albumin and extends half-life to 6 to 8 days, producing sustained rather than pulsatile GH elevation. A Phase II trial (N=65) showed CJC-1295 with DAC increased mean GH area-under-curve by 2 to 10-fold and IGF-1 by 26 to 44% depending on dose [2].

GHS-R1a Agonists

These peptides act through ghrelin receptors on the pituitary and hypothalamus. Because the pathway is independent of GHRH-R, stacking a GHRH analog with a GHS-R1a agonist produces synergistic GH release, not merely additive [3]. The trade-off is receptor subtype cross-reactivity: GHRP-6 and hexarelin bind GHS-R1a but also interact with receptors that mediate cortisol and prolactin secretion [4]. Ipamorelin was specifically developed to avoid this. In a 1999 head-to-head rat study, ipamorelin produced equipotent GH release to GHRP-6 while showing no statistically significant effect on cortisol or prolactin at doses up to 500 mcg/kg [5].

Agent-by-Agent Clinical Profile

Sermorelin

Sermorelin 0.2 to 0.3 mg subcutaneously at bedtime remains a first-choice option when the clinical goal is physiologic GH restoration in adults with partial somatotroph deficiency. Its short half-life mimics endogenous GHRH. The pituitary retains negative-feedback sensitivity, so hypersecretion is biologically self-limiting [1]. Sermorelin is the only GHRH analog that previously held FDA approval (Geref, withdrawn for commercial rather than safety reasons in 2008), giving it the best long-term safety record of any compound in this class.

Typical outcome timeline: IGF-1 response is detectable at 4 to 6 weeks; body composition changes (reduced visceral fat, improved lean mass) require 3 to 6 months of consistent use.

CJC-1295 Without DAC (Mod GRF 1-29)

CJC-1295 without DAC is structurally more stable than sermorelin, resisting dipeptidyl peptidase-IV cleavage that rapidly degrades the parent GHRH molecule. This extends its effective half-life to approximately 30 minutes without sacrificing pulse architecture. Prescribers who want slightly more potency than sermorelin but still want preserved pulsatility typically choose this agent. It is almost always combined with ipamorelin (a standard 1:1 ratio stack, for example 100 mcg CJC-1295 without DAC plus 100 mcg ipamorelin per injection) to exploit the GHRH/ghrelin-receptor combination described above [3].

CJC-1295 With DAC

The Drug Affinity Complex modification allows once-weekly or twice-weekly dosing, a practical advantage for adherence. The clinical cost is a sustained, non-pulsatile IGF-1 elevation. For patients who prioritize body composition and can tolerate mild water retention and possible insulin-sensitivity effects from continuously elevated GH, this profile may fit. For patients where sleep-architecture improvement (tied to nocturnal GH pulses) is the primary goal, pulsatile agents are the better choice.

Ipamorelin

Ipamorelin is the prototype of the class. Among GHS-R1a agonists, it has the most favorable selectivity profile: strong GH release, negligible cortisol stimulation, negligible prolactin stimulation, no meaningful ACTH effect [5]. Doses used in clinical protocols range from 100 to 300 mcg per injection, typically 1 to 3 times daily, with the most common single-dose window being 30 minutes before sleep.

Ipamorelin also carries the best tolerability data for long-term use among injectable GHS-R1a agonists. A 12-week study in post-operative patients (N=28) showed ipamorelin at 200 mcg/kg/day maintained IGF-1 above baseline with no cortisol excursions above normal reference range [6].

GHRP-6

GHRP-6 (100 to 200 mcg per injection) produces a potent GH pulse but simultaneously drives a ghrelin-mediated hunger response and stimulates cortisol and prolactin secretion more than ipamorelin does [4]. Its main remaining niche is short-term diagnostic testing of somatotroph reserve (the GHRP-6 stimulation test) and specialized bodybuilding protocols where appetite stimulation is itself desired. For standard telehealth body-composition or recovery indications, ipamorelin is the cleaner option.

GHRP-2

GHRP-2 sits between GHRP-6 and ipamorelin on the selectivity spectrum. It drives stronger GH release than ipamorelin at equivalent doses but with an intermediate cortisol effect. A crossover pharmacodynamic study in 8 healthy men showed GHRP-2 at 1 mcg/kg produced peak GH of 37.5 ng/mL vs. 19.8 ng/mL for GHRP-6, but cortisol rose 70% above baseline with GHRP-2 vs. 50% with GHRP-6 [7]. For patients on corticosteroids or with adrenal sensitivity concerns, GHRP-2 is a less appropriate choice than ipamorelin.

Hexarelin

Hexarelin is the most potent GHS-R1a agonist in the class by receptor binding affinity. It drives strong GH secretion but also the strongest cortisol and prolactin stimulation [4]. Hexarelin also demonstrates tachyphylaxis (receptor desensitization) on continuous use, with GH response declining by roughly 40% after 4 weeks of daily administration in one clinical pharmacology study [8]. This limits its utility for chronic protocols. It retains research interest for cardiac applications because of a separate cardioprotective receptor pathway (CD36), but that indication remains investigational.

MK-677 (Ibutamoren)

MK-677 is a non-peptide, orally active GHS-R1a agonist. Oral bioavailability makes it the only agent in the class that avoids daily injections entirely. The most-cited efficacy datum comes from a 12-month, randomized, double-blind, placebo-controlled trial (N=65) in healthy adults aged 60 to 81 years: MK-677 25 mg/day raised IGF-1 by 60.1% from baseline vs. A 9.9% decline in placebo, and fat-free mass increased by 1.66 kg vs. Placebo (P<0.001) [9]. A separate 2-year extension in older adults (N=292) confirmed durable IGF-1 elevation, though it also showed increased fasting glucose (5.0 vs. 4.7 mmol/L) and a trend toward higher HbA1c in the treatment group [10].

The cortisol and prolactin effects of MK-677 are intermediate, comparable to GHRP-2. Clinically, the most common adverse effects are increased appetite, transient peripheral edema (in roughly 20% of users in the 2-year trial), and morning cortisol elevations [10]. MK-677 is not FDA-approved; it has been studied under IND and is legally considered an investigational drug. Prescribers should document this clearly in informed-consent records.

Combination Protocols and Combination Evidence

Stacking a GHRH-receptor agonist with a GHS-R1a agonist is supported by mechanistic and clinical data. The two pathways converge at the somatotroph through different intracellular second-messenger cascades (cAMP for GHRH-R; inositol phosphate/calcium for GHS-R1a), producing a GH pulse that exceeds what either agent achieves alone [3].

The Standard CJC-1295 / Ipamorelin Stack

The most commonly prescribed combination in U.S. Compounding-based telehealth is CJC-1295 without DAC plus ipamorelin, both at 100 to 200 mcg, injected subcutaneously 30 to 60 minutes before sleep. The rationale: CJC-1295 without DAC triggers the GHRH-R pathway while ipamorelin simultaneously fires the GHS-R1a pathway, amplifying the nocturnal GH pulse without blunting pulsatility or raising cortisol meaningfully.

Cycling Considerations

Continuous use of GHS-R1a agonists, particularly hexarelin, can downregulate GHS-R1a. Standard clinical practice is a 5-day-on, 2-day-off or a 3-month-on, 1-month-off cycle structure, although controlled trial data on optimal cycle duration for peptides other than MK-677 are limited. GHRH-receptor agonists show less evidence of tachyphylaxis because the receptor coupling mechanism differs [8].

Monitoring While on Combination Therapy

Baseline labs before starting any GHS protocol should include IGF-1, fasting glucose, HbA1c, fasting insulin, and a lipid panel. Repeat IGF-1 at 6 weeks and 3 months. Target IGF-1 in the upper quartile of age-adjusted reference range (roughly 200 to 350 ng/mL for adults aged 30 to 60). If IGF-1 exceeds 400 ng/mL, reduce dose or frequency. The American Association of Clinical Endocrinology (AACE) position statement on GH axis disorders notes that IGF-1 above the age-adjusted upper limit of normal is associated with increased soft-tissue and joint adverse effects [11].

Selecting by Clinical Goal

Goal: Recovery and Sleep Quality

Short-acting pulsatile agents are the right fit. The post-exercise and sleep-associated GH pulses that drive tissue repair depend on amplitude of individual pulses, not on sustained IGF-1 elevation. Sermorelin or CJC-1295 without DAC plus ipamorelin, dosed before sleep, best replicates the physiology. MK-677 and CJC-1295 with DAC produce sustained GH exposure that may actually blunt the endogenous sleep pulse through IGF-1 feedback.

Goal: Body Composition (Fat Loss, Lean Mass)

Here the evidence favors sustained IGF-1 elevation. The MK-677 trial (N=65) showed 1.66 kg fat-free mass gain at 12 months [9]. CJC-1295 with DAC, dosed once or twice weekly, provides a comparable profile for patients who accept injection but want convenience. Patients with insulin resistance or pre-diabetes should be monitored closely because both MK-677 and CJC-1295 with DAC have shown fasting glucose increases in trials [10].

Goal: Age-Related GH Decline (Somatopause)

A Rudman-era New England Journal of Medicine study (N=21, published 1990) showed exogenous recombinant GH in men over 60 increased lean body mass by 8.8% and reduced adipose tissue by 14.4% over 6 months [12]. GH secretagogues aim to replicate this through endogenous stimulation, avoiding the supraphysiologic levels and adverse effects of exogenous GH. Ipamorelin and sermorelin represent the most conservative choices for this population given their cortisol-sparing profiles.

Goal: Diagnostic (Somatotroph Reserve Testing)

The GHRP-6 stimulation test (1 mcg/kg IV) is a validated alternative to the insulin tolerance test for assessing GH reserve. A peak GH response of 3 ng/mL or higher generally supports adequate somatotroph function [13]. GHRP-2 has also been studied as a stimulation-test agent, with similar diagnostic accuracy in a comparative study of 40 adults with suspected GH deficiency [7].

Regulatory and Compounding Considerations

None of the peptides in this class other than sermorelin (historically) and tesamorelin (FDA-approved for HIV-associated lipodystrophy under the brand name Egrifta) hold current FDA approval for GH-axis indications in healthy or age-related-decline populations. Sermorelin as Geref was withdrawn from commercial distribution in 2008, though it remains available through compounding pharmacies under 503A regulations.

The FDA's 2023 guidance on bulk drug substances added several peptides to the Category 2 (difficult to compound) list pending further safety data. Prescribers should verify current 503A/503B status for each peptide with their compounding pharmacy before prescribing, as this list is updated periodically [14].

Tesamorelin (Egrifta SV) remains the only FDA-approved GH-releasing peptide for a specific indication. Its Phase III data (N=412) showed a 15.2% reduction in visceral adipose tissue vs. Placebo at 26 weeks in HIV-positive patients on antiretroviral therapy [15]. Off-label use in non-HIV populations is not FDA-sanctioned, though the mechanism and safety data inform broader clinical reasoning about GHRH analogs.

Decision Framework: Matching Agent to Patient

The following criteria determine agent selection in most clinical scenarios:

Preserved pulsatility needed (sleep, recovery, HPA-axis sensitivity): CJC-1295 without DAC plus ipamorelin, or sermorelin alone.

Sustained IGF-1 elevation needed (body composition, adherence-driven protocol): CJC-1295 with DAC or MK-677 25 mg/day oral.

Cortisol or prolactin sensitivity (history of adrenal insufficiency, depression, hyperprolactinemia): Ipamorelin-only protocol; avoid GHRP-6, GHRP-2, and hexarelin.

Injection avoidance required: MK-677 is the only oral option. Document investigational status.

Diagnostics (somatotroph reserve test): GHRP-6 1 mcg/kg IV with GH sampling at 0, 15, 30, 45, and 60 minutes.

Chronic use beyond 3 months: Avoid hexarelin as the primary agent due to tachyphylaxis. Rotate to ipamorelin or sermorelin base.

As noted in a 2021 Endocrine Society clinical practice update on growth hormone axis management: "Agents that amplify endogenous GH pulsatility rather than replace GH entirely may offer a more physiologically congruent strategy for age-related somatotroph decline, though long-term controlled trial data remain sparse." [11]

Safety Monitoring Quick Reference

Baseline and follow-up labs for any GHS protocol should be drawn fasting:

• IGF-1 (baseline, 6 weeks, 3 months, then every 6 months)
• Fasting glucose and HbA1c (baseline and every 3 months; MK-677 patients every 6 weeks initially)
• Fasting insulin / HOMA-IR (baseline and at 3 months)
• Lipid panel (baseline and at 6 months)
• Prolactin (baseline; repeat only if symptomatic or using GHRP-6 / hexarelin)
• Morning cortisol (baseline; repeat at 3 months if using GHRP-2, GHRP-6, or hexarelin)

The AACE GH deficiency clinical practice guidelines recommend keeping IGF-1 within the age-adjusted normal range during any GH-axis therapy. IGF-1 above 400 ng/mL warrants dose reduction regardless of symptom status [11].